

Aryloxy Diester Phosphoramidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of V γ 9/V δ 2 T-Cell Immune Responses

Hachemi Kadri, Taher E. Taher, Qin Xu, Maria Sharif, Elizabeth Ashby, Richard T. Bryan, Benjamin E. Willcox,* and Youcef Mehellou*

Cite This: *J. Med. Chem.* 2020, 63, 11258–11270

Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: V γ 9/V δ 2 T-cells are activated by pyrophosphate-containing small molecules known as phosphoantigens (PAGs). The presence of the pyrophosphate group in these PAGs has limited their drug-like properties because of its instability and polar nature. In this work, we report a novel and short Grubbs olefin metathesis-mediated synthesis of methylene and difluoromethylene monophosphonate derivatives of the PAG (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBP) as well as their aryloxy diester phosphoramidate prodrugs, termed ProPAgens. These prodrugs showed excellent stability in human serum ($t_{1/2} > 12$ h) and potent activation of V γ 9/V δ 2 T-cells (EC_{50} ranging from 5 fM to 73 nM), which translated into sub-nanomolar $\gamma\delta$ T-cell-mediated eradication of bladder cancer cells *in vitro*. Additionally, a combination of *in silico* and *in vitro* enzymatic assays demonstrated the metabolism of these phosphoramidates to release the unmasked PAG monophosphonate species. Collectively, this work establishes HMBP monophosphonate ProPAgens as ideal candidates for further investigation as novel cancer immunotherapeutic agents.



INTRODUCTION

V γ 9/V δ 2 T-cells are the dominant subtype of human $\gamma\delta$ T-cells in adult peripheral blood.¹ They are involved in immune responses to many diseases such as tuberculosis, leprosy, typhoid, malaria, and toxoplasmosis.¹ Studies in primate models have also implicated V γ 9/V δ 2 T-cells in immunity to *Mycobacterium tuberculosis*.² These cells have been shown to target and lyse a diverse range of cancer cells *in vitro*.¹ Together, these observations have made the V γ 9/V δ 2 subset a major focus of investigation for the therapeutic exploitation of $\gamma\delta$ T-cells.³

To date, a handful of small molecule activators of V γ 9/V δ 2 T-cells have been reported. Among these are the two aminobisphosphonate drugs, risedronate and zoledronate (Figure 1), which are currently used clinically to treat




Figure 1. Chemical structure of reported small molecule V γ 9/V δ 2 T-cell activators; HMBPP (EC_{50} : 60–500 pM),^{19–21} IPP (EC_{50} : 1–10 μ M),^{22,23} risedronate (EC_{50} : 0.08–5 μ M),^{24,25} and zoledronate (EC_{50} : 0.003–0.5 μ M) [this work and Davey *et al.*²⁰]

osteoporosis and some types of cancer.^{4–6} These agents inhibit isopentenyl pyrophosphate (IPP) catabolism *via* farnesyl diphosphate (FPP) synthase, leading to intracellular IPP accumulation, which ultimately results in V γ 9/V δ 2 T-cell activation.^{7–9} Beyond these two compounds, the microbially derived phosphoantigen (PAG) (*E*)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) and the host-derived PAG IPP itself are both established V γ 9/V δ 2 T-cell activators (Figure 1).^{10,11} These are known to activate V γ 9/V δ 2 T-cells by binding the type-1 transmembrane protein butyrophilin 3A1 (BTN3A1) that is expressed on target cells.¹² Although the binding site for these PAGs initially remained unclear amid conflicting reports as to whether they bind the extracellular or intracellular domains of this transmembrane protein, there is now compelling evidence to support the notion that HMBPP binds the intracellular B30.2 domain of butyrophilin 3A1, triggering a conformational change.^{12–16} Although the molecular events subsequent to this are unclear, PAG-mediated activation is dependent upon target cells co-expressing

Received: July 15, 2020

Published: September 15, 2020



BTN3A1 alongside a second family member, butyrophilin 2A1 (BTN2A1), with which it associates and which is able to directly ligate the V γ 9V δ 2 T-cell receptor (TCR).^{17,18} One plausible sensing mechanism involves PAg exposure regulating BTN3A1-mediated recruitment of an additional molecule¹⁸ that in combination with BTN2A1, forms a “composite ligand” for the V γ 9V δ 2 TCR complex, thereby triggering activation.¹⁸

Encouraged by the potency of the PAg HMBPP in activating V γ 9/V δ 2 T-cells, EC₅₀ = 60–500 pM,^{19–21} and given our interest in developing phosphate- and phosphonate-containing drugs,^{26–28} we previously reported the application of McGuigan’s phosphoramidate prodrug technology^{29,30} to the monophosphate derivative of HMBPP, that is, (*E*)-4-hydroxybut-2-enyl phosphate (HMBP), as a means of improving its drug-like properties.²⁹ In this phosphoramidate prodrug approach, the monophosphate or monophosphonate groups are masked by an aryl group and an amino acid ester (Figure 2), which are both enzymatically cleaved off inside




Figure 2. Chemical structures of HMBP ProPAGs (previous work) and the ProPAGs of their phosphonate derivatives (this work) as well as a general indication of their stability and V γ 9/V δ 2 T-cell activation.

cells to release the monophosphate or monophosphonate species.²⁹ As these are prodrugs of PAg, we previously²⁰ termed them ProPAGs to distinguish them from ProTides,²⁹ prodrugs of nucleotides. Although the HMBP ProPAGs that we reported previously²⁰ exhibited potent activation of V γ 9/V δ 2 T-cells (EC₅₀ = 0.45–10.62 nM), their stability was poor ($t_{1/2}$ < 30 min).²⁰ The observed instability was shown to be because of the cleavage of the –P–O– bond of these compounds.²⁰ To circumvent this problem, we herein report our application of McGuigan’s phosphoramidate prodrug technology to HMBP methylene and difluoromethylene monophosphonates to generate their aryloxy diester phosphoramidate prodrugs (Figure 2).

RESULTS AND DISCUSSION

Design and Synthesis of HMBP Monophosphonate ProPAGs. In the design of HMBP monophosphonates, we switched the liable –O–PO(OH)₂ to a more stable –CH₂–PO(OH)₂ or –CF₂–PO(OH)₂ bond. The introduction of a phosphonate bond (–CH₂–PO(OH)₂) instead of a phosphate one (–O–PO(OH)₂) is quite common in drug discovery and has been used with success in addressing stability issues observed with phosphate-containing compounds.³¹ A prime example of this are the antiviral drugs *cidofovir* and *adefovir*.³¹ Although the change from a –O–PO(OH)₂ bond to a –CH₂–PO(OH)₂ bond achieves better stability, the pK_a value of the second deprotonation of the phosphonate group (pK_a = 7.49) is significantly different from that of the phosphate group

(pK_a = 6.31) (Figure 3).³² As a result, this affects their full ionization under physiological pH (<7.4) and, hence, their





Figure 3. pK_a values of phosphate and different phosphonate groups.

binding to the target protein, which optimally requires the full ionization of the phosphate group to bind a positively charged pocket (arginine-rich) on the BTN3A1 intracellular B30.2 domain.¹⁶ To address this, switching the phosphate (–O–PO(OH)₂) bond to a difluoromethylene phosphonate (–CF₂–PO(OH)₂) has emerged as a better substitution because these have excellent stability in physiological environments coupled with a pK_a value for the second deprotonation (pK_a = 5.5) as acidic as that of the native phosphate (Figure 3).³² Therefore, under physiological pH, the –CF₂–PO(OH)₂ will be fully deprotonated akin to natural phosphate groups –O–PO(OH)₂, and this ensures similar binding to that achieved by the natural phosphate group.

With this in mind, we synthesized the ProPAGs of both HMBP methylene and difluoromethylene monophosphonates (4a–d and 9a–d, Scheme 1). Previously, the synthesis of HMBP methylene monophosphonate prodrugs was achieved in five steps starting from dimethyl homoprenylphosphonate,³³ which itself has to be prepared in two steps from the commercially available 3-methylbut-2-en-1-ol.¹⁹ Some of these reactions are low yielding such as the oxidation of the side chain to introduce HMBP’s side chain, the hydroxyl group.³³ Notably, to date, no synthesis of HMBP difluoromethylene monophosphonate prodrugs has been reported.

In order to accomplish the synthesis of HMBP methylene and difluoromethylene monophosphonate prodrugs (4a–d and 9a–d, Scheme 1), we employed the Grubbs olefin metathesis³⁴ in the construction of these prodrugs. Using commercially available starting materials, our new synthetic approach allowed the rapid and efficient synthesis of the PAg ProPAGs in three steps for HMBP methylene monophosphonate prodrugs (4a–d) and four steps for HMBP difluoromethylene monophosphonate prodrugs (9a–d) as shown in Scheme 1.

The synthesis of ProPAGs 4a–d started by treating the commercially available diethyl 3-butenylphosphonate (1) with bromotrimethylsilane (TMSBr) at room temperature to remove the ethoxy groups and generate the phosphonic acid derivative.³⁵ This was followed by a chlorination reaction using oxalyl chloride in the presence of a catalytic amount of DMF. The product of this reaction, 2, was subsequently treated with phenol in the presence of triethylamine and then with the appropriate amino acid ester to yield phosphoramidates 3a–d in moderate to good yields (38–61%). Next, these compounds

Scheme 1^a

^aReagents and conditions: (i) TMSBr, DCM, rt, 2 h then (COCl)₂, DMF cat, DCM, rt, 18 h; (ii) a. Phenol, Et₃N, DCM, -78 °C for 30 min then rt, 3 h; b. Substituted L-alanine ester hydrochloride, Et₃N, DCM, rt, 12 h, yields: 38–61%; (iii) 2-methyl-2-propenol, 1,4-benzoquinone, Hoveyda–Grubbs catalyst 2nd generation, DCM, rt, yields: 57–64%; (iv) diethyl (bromodifluoromethyl)phosphonate, DMF, zinc powder, rt, N₂, 3 h then CuBr, allyl bromide, rt, 40 h; (v) (i) TMSBr, DCM, rt, 2 h then (COCl)₂, DMF cat, DCM, rt, 18 h; (ii) a. Phenol, Et₃N, DCM, -78 °C for 30 min then rt, 3 h; b. Substituted L-alanine ester hydrochloride, Et₃N, DCM, rt, 12 h, yields: 24–46%; and (iii) 2-methyl-2-propenol, 1,4-benzoquinone, Hoveyda–Grubbs Catalyst 2nd generation, DCM, rt, yields: 58–69%.




Figure 4. Stability of HMBP monophosphonate ProPAGen **9a** in human serum at 37 °C for 12 h as monitored by ³¹P NMR.

underwent Grubbs olefin metathesis with 2-methyl-2-propenol employing the Hoveyda–Grubbs second generation catalyst in the presence of 1,4-benzoquinone to prevent alkene isomerization.³⁶ This gave ProPAGens **4a–d** in good yields (57–64%).

For the synthesis of ProPAGens **9a–d**, the commercially available diethyl (bromodifluoromethyl)phosphonate **5** was reacted with allyl bromide in the presence of zinc and copper bromide in DMF as reported.³⁷ The generated compound, **6**, was subsequently chlorinated and then treated with phenol and the appropriate amino acid ester to yield phosphoramidates **8a–d** in moderate yields (24–46%) as described for the synthesis of compounds **3a–d** above. Subsequently, these phosphoramidates were treated with 2-methyl-2-propenol in the presence of Hoveyda–Grubbs second generation catalyst

and catalytic amounts of 1,4-benzoquinone.³⁶ The final ProPAGens **9a–d** were generated in good yields (58–69%).

In terms of the design of the prodrugs, L-alanine was used as the amino acid of choice in the synthesis of these ProPAGens because it has historically shown optimum biological activity,³⁰ while the phenol motif was chosen as it has been used successfully in the discovery of two FDA-approved drugs: sofosbuvir and tenofovir alafenamide.²⁹ Four different ester motifs were chosen in the synthesis of ProPAGens **4a–d** and **9a–d**, methyl (Me), isopropyl (iPr), *tert*-butyl (tBu), and benzyl (Bn) because they show varying biological activities that range from low (tBu) to high (Bn).^{20,26,29}

Serum Stability of HMBP Monophosphonate ProPAGens. Because the motive for synthesizing the HMBP monophosphonate ProPAGens was to address the poor stability

observed with their parent HMBP monophosphate ProPAGens,²⁰ upon the completion of their synthesis, we first studied their stability in human serum. As an example, we incubated the difluoromethylene ProPAGEN 9a with human serum at 37 °C for 12 h and monitored the sample by ³¹P NMR, as we reported previously.²⁶ As shown in Figure 4, the ³¹P NMR spectra of ProPAGEN 9a showed six phosphorous peaks because of the two diastereoisomers that arise from the chiral phosphorous center, which is typical of these prodrugs, and the phosphorous coupling with the fluorine atoms. Following the addition of human serum and monitoring of the sample by ³¹P NMR, these original 9a ³¹P NMR peaks remained present through the 12 h of the study, and no new ³¹P NMR peaks were observed. A similar stability profile was observed with the methylene ProPAGEN 4d (Figure S1).

Collectively, these data indicated the superior stability of these compounds relative to that previously observed with HMBP monophosphate ProPAGens.²⁰ The observed $-\text{CH}_2-\text{PO}(\text{OH})_2$ and $-\text{CF}_2-\text{PO}(\text{OH})_2$ groups' stability profile is in line with what has been observed for difluoromethyl and methyl phosphonates.³¹

Metabolism of HMBP Monophosphonate ProPAGens.

The breakdown of aryloxy triester phosphoramidate and aryloxy diester phosphonamidate prodrugs is known to be mediated by two enzymes: carboxypeptidase Y and a phosphoramidase-type enzyme, for example, Hint-1 (Figure 5A).²⁹ Indeed, upon cell entry, the breakdown of these phosphonate masking groups is initiated by hydrolysis of the ester motif by carboxypeptidase Y, and this generates a carboxylate group (A), which performs a nucleophilic attack onto the phosphonate group. This leads to the loss of the aryl group and the formation of a highly unstable five-membered heterocyclic ring (B), which is rapidly opened up by a water molecule to generate the amidate metabolite C. Finally, a phosphoramidase-type enzyme, for example, Hint-1 cleaves the P–N bond and releases the monophosphonate species. As this postulated mechanism of McGuigan's phosphoramidate prodrugs has been generated through extensive studies on nucleoside monophosphate aryloxy triester phosphoramidate prodrugs, we investigated whether this was the case for non-nucleosides, PAg aryloxy diester phosphonamidate prodrugs in this case. Thus, ProPAGEN 9b was incubated *in vitro* with recombinant carboxypeptidase Y at 37 °C, and the reaction was then monitored by ³¹P NMR. As shown in Figure 5B, at $t = 0$ h, the ³¹P NMR scan showed the presence of six phosphorous peaks, $\delta_p = 9.25, 9.52, 9.71, 10.08, 10.19,$ and 10.51 ppm, as expected. However, 30 min after the addition of recombinant carboxypeptidase Y and incubation at 37 °C, the phosphorous peaks corresponding to ProPAGEN 9b were almost consumed and three prominent phosphorous peaks, $\delta_p = 6.50, 6.90,$ and 7.20 ppm, appeared. These peaks remained present throughout the 15 h period of this study. The disappearance of the six phosphorous peaks corresponding to ProPAGEN 9b indicates that the carboxypeptidase Y cleaved off the ester motif and triggered the breakdown of the aryloxy diester phosphoramidate moiety as depicted in Figure 5A. Given that the sample lacks Hint-1, the anticipated product from this *in vitro* study is metabolite C (Figure 5A). This notion was supported by the fact that the loss of the ester and phenyl groups from the parent ProPAGEN and the generation of the corresponding metabolite C leads to the loss of the chirality at the phosphorous center. Hence, the ³¹P NMR would show only a triplet because of the phosphorous–




Figure 5. *In vitro* carboxypeptidase-mediated breakdown of HMBP phosphonate ProPAGEN 9b. (a) Postulated mechanism of aryloxy diester prodrugs metabolism. (b) ³¹P NMR spectrum of ProPAGEN 9b alone and at different time points, following incubation with recombinant carboxypeptidase Y at 37 °C for 15 h.

fluorine coupling, and such a splitting pattern was observed in our study (Figure 5B). To confirm whether the product generated after 15 h was metabolite C, the sample was analyzed by LC–MS, and indeed, a new major peak was detected by high-performance liquid chromatography (HPLC) and this had a mass that corresponded to metabolite C (Figure S2).

In order to probe whether metabolite C could be processed by Hint-1 to cleave the P–N bond and release the monophosphonate species,^{38–40} we performed *in silico* docking of metabolite C into the cocrystal structure of Hint-1 with AMP (Figure S3). Analysis of the different predicted poses




Figure 6. *In vitro* ProAgen-mediated activation of V γ 9/V δ 2 T-cells, following overnight incubation with HMBPP, zoledronate, and HMBPP ProPAGens. Levels of activation are represented as % of V γ 9/V δ 2 T-cells that are CD69+ CD25+. Data is shown as mean \pm SE ($n = 4$). (A) Activation of V γ 9/V δ 2 stimulated by ProPAGens 4a–d. (B) Activation of V γ 9/V δ 2 stimulated by ProPAGens 9a–d. (C) Activation of V γ 9/V δ 2 stimulated by HMBPP and zoledronate. (D) EC₅₀ values calculated based on the results of the activation assay. CLogP values were calculated using ChemDraw.

indicated that the amidate moiety of metabolite C was positioned in a pocket that included the key catalytic Hint-1 amino acid residues (serine 107, histidines 112 and 114) (Figure S3). Such a position suggests that metabolite C is likely to be processed by Hint-1 to release the unmasked monophosphonate, in agreement with previous conclusions.²⁷

Together, the *in vitro* carboxypeptidase Y assay and the Hint-1 *in silico* docking support the metabolism of HMBP phosphonate ProPAGens to release the unmasked monophosphonate species.

V γ 9/V δ 2 T-cell Activation and Cancer Cells Lysis by HMBP Monophosphonate ProPAGens. Once the synthesis, stability, and metabolism of HMBP monophosphonate ProPAGens were established, they were subsequently studied for their ability to activate V γ 9/V δ 2 T-cells and lyse cancer cells *in vitro*. For this, peripheral blood mononuclear cells (PBMCs) containing V γ 9/V δ 2 T-cells derived from healthy donors were incubated with increasing concentrations of HMBPP, zoledronate, or HMBP ProPAGens 4a–d and 9a–d (up to 100 μ M) (Figure 6). Peripheral blood $\gamma\delta$ T-cells lack appreciable levels of surface CD69 or CD25 under steady-state conditions, but TCR stimulation upregulates both T-cell activation markers.⁴¹ PAg-responsive V γ 9/V δ 2 T-cells were then assessed for the upregulation of CD69 and CD25.

The results showed that the natural PAg HMBPP exhibited significant activation of V γ 9/V δ 2 T-cells, EC₅₀ = 0.145 nM (Figure 6C), comparable to its reported potency.^{19,21} Addi-

tionally, zoledronate showed a much weaker activation, EC₅₀ \approx 3,060 nM as expected (Figure 6C). Initially, we tested the activation of V γ 9/V δ 2 T-cells using all of the eight HMBP phosphonate ProPAGens (4a–d and 9a–d) and employing concentrations ranging from 10 pM to 100 μ M (Figures 6A,B and S4). For simplicity, the data presented in Figure 6A–C only show the activation up to 10 μ M, while a graphical representation of the data up to 100 μ M is provided in Figure S4. All of the ProPAGens showed potent activation of V γ 9/V δ 2 T-cells with potencies (EC₅₀) comparable to the natural PAg HMBPP. Interestingly, two ProPAGens 4d and 9d, which are the benzyl ester prodrugs, exhibited far more potent activation of V γ 9/V δ 2 T-cells: even at 10 nM, these two prodrugs achieved >50% activation of V γ 9/V δ 2 T-cells. To determine the EC₅₀ values of these compounds, we repeated the V γ 9/V δ 2 T-cells activation assay using sub-nanomolar concentrations (from 1 attomolar [aM] to 100 μ M) (Figure S5). The data showed that ProPagen 4d had an EC₅₀ = 9.15 fM, whereas 9d had an EC₅₀ = 4.97 fM (Figure 6D), demonstrating that these ProPAGens are 15,000–30,000-fold more potent than the PAg HMBPP in the same assay. To the best of our knowledge, this makes ProPAGens 4d and 9d the most potent small molecule V γ 9/V δ 2 T-cells activators reported to date.

Notably, at the highest concentration studied (100 μ M), the activation of V γ 9/V δ 2 T-cells by ProPAGens 4d and 9d was less than that achieved with 10 μ M (Figure S4). This could be explained by negative feedback mechanisms induced by




Figure 7. Cytotoxicity of $V\gamma 9/V\delta 2$ T-cells toward ProPAGEN-treated T24 cells. % killing represents % GFP + eFluor780+ cells (*i.e.* dead T24 cells). (A) Cytotoxicity of $V\gamma 9/V\delta 2$ T-cells toward T24 cells treated with ProPAGens **4c**, **4d**, **9c**, and **9d** at different effector/target ratios. Ratio 0:1 refers to the basal effect of ProPAGens on T24 cells in the absence of effectors. (B,C) Cytotoxicity of ProPAGens **4c**, **4d**, **9c**, and **9d** (used at 10 pM) compared to the 10 pM HMBPP-induced effect after subtracting the basal cytotoxic effect of $V\gamma 9/V\delta 2$ on untreated T24 cells. Data is shown as mean \pm SE ($n = 3$). Statistical analysis was performed using one-way ANOVA and Tukey's multiple comparisons test. * $p < 0.05$.

antigen overstimulation that lead to downregulation of the TCR, subsequently resulting in lower expression of the CD25 activation marker.⁴²

Although the potencies of compounds **4d** and **9d** are significantly higher than the other HMBP ProPAGens studied in this work (Figure 6D), this is consistent with other studies of this type of prodrug when used as anticancer agents. An example of this is the aryloxy triester phosphoramidate prodrugs of the anticancer agent gemcitabine, where the benzyl ester phosphoramidates exhibit potent sub-micromolar potencies across four cancer cell lines compared to the isopropyl ester prodrugs, which had an $IC_{50} > 5 \mu M$.⁴³ Additionally, HMBP methylene phosphoramidate prodrugs using glycine as an amino acid have been shown to exhibit sub-nanomolar activation of $V\gamma 9/V\delta 2$ T-cells,³³ and this was the same with mixed aryl prodrugs of HMBP.^{44,45} Notably, glycine phosphoramidates often generate less potent prodrugs compared to the *L*-alanine counterparts.²⁹ Thus, the sub-nanomolar potencies of $V\gamma 9/V\delta 2$ T-cell activation by HMBP prodrugs seems to be consistent and correlates with the lipophilicity of the prodrugs.

Considering the structure–activity relationship (SAR) of our HMBP ProPAGens, we did not observe significant differences between the methyl and difluoromethyl phosphonate ProPAGens, while the $V\gamma 9/V\delta 2$ T-cell activation potency varied with the ester motif used. Indeed, ProPAGens with the benzyl ester groups (**4d** and **9d**) exhibited the most potent activation of $V\gamma 9/V\delta 2$ T-cells, followed by those with methyl and isopropyl ester groups, and the *t*Bu-bearing ProPAGens exhibited the least potency in activating $V\gamma 9/V\delta 2$ T-cells within the series presented here.

Such an influence of the ester group on the biological activity of this type of phosphoramidate prodrugs is consistent with the established SAR of these prodrugs.²⁹ The difference in biological activity in such prodrugs is because of the differential lipophilicity between these compounds and the efficiency of the esterases in hydrolyzing the ester groups. For instance, it is now well-established that phosphoramidates with a benzyl ester often show the best biological activity because they often have the highest lipophilicity, which facilitates their efficient passive uptake into cells as well as rapid hydrolysis of this ester group by esterases.²⁹

In contrast to the benzyl moieties, the *t*Bu esters of phosphoramidates are known to be metabolized relatively slowly by esterases, which explains their relatively poor biological activity as compared to their benzyl ester phosphoramidates. This may also explain the superior $V\gamma 9/V\delta 2$ T-cell activation by the benzyl ester ProPAGens **4d** and **9d** compared to the other studied ProPAGens—the 20 h activation assay described here is often sufficient for the benzyl ester prodrugs to be metabolized, while it may be of too short duration for the other nonbenzyl ester ProPAGens to be metabolized to levels that generate intracellular concentrations of the monophosphonate species sufficient to induce potent $V\gamma 9/V\delta 2$ T-cell activation. Indeed, classically, the potency of aryloxy triester phosphoramidates is determined after 48 or 72 h, and in such studies, the nonbenzyl ester aryloxy triester phosphoramidates (apart from the *t*Bu esters) show potent pharmacological activity.^{43,46}

Given the high potency of HMBPP ProPAGEN presented in this work, we subsequently studied their specificity toward the activation of $V\gamma 9/V\delta 2$ T-cells. For this, we repeated the same

V γ 9/V δ 2 T-cell activation assay using ProPAGens **4d** and **9d** (1 aM and 100 μ M concentrations) and also, as a specificity control, we assessed the activation of CD8⁺ $\alpha\beta$ T-cells, which are activated by peptides.⁴⁷ As expected, our data confirmed that these prodrugs did not induce any activation of $\alpha\beta$ T-cells (Figure S6). The specificity of these HMBP prodrugs is, therefore, in line with previous observations.²⁰

Encouraged by the potency and specificity of our HMBP ProPAGens, especially **4d** and **9d**, we subsequently studied their ability to sensitize the urinary bladder carcinoma cell line T24 for targeted killing by *in vitro* expanded V γ 9/V δ 2 T-cells. In brief, T24 cells were retrovirally transduced to express GFP. These GFP + T24 cells were incubated in media containing 10 pM HMBPP or the indicated HMBPP ProPAGens for a period of 4 h. Media-only treated controls (no drug) were also included. The cells were then washed and cocultured with *ex vivo* expanded V γ 9/V δ 2 T-cells overnight at different effector/target ratios, and the viability of GFP + T24 cells was then measured on the following day. In the absence of effectors (V γ 9/V δ 2 T-cells), ProPAGEN-pulsed T24 cells were poorly targeted, but upon pulsing for 4 h with V γ 9/V δ 2 T-cells, T24 cells were specifically lysed with increasing effector/target ratio, particularly with ProPAGens **4d** and **9d** (Figure 7A). In addition, the sensitizing effects of ProPAGens **4d** and **9d** are evidently much more potent in comparison to HMBPP and the *t*Bu ester ProPAGens **4c** and **9c** (Figure 7B,C). Notably, ProPAGEN **9d** showed more significant sensitizing effects compared to HMBPP and ProPAGEN **9c** at 1:1 effector/target ratio (Figure 7B). Collectively, these results are consistent with our previous²⁰ and current findings that benzyl ester ProPAGens are the most potent activators of V γ 9/V δ 2 T-cells based on the data generated by *in vitro* activation assays, while, alternatively, the *t*Bu ester ProPAGens are comparatively less potent.

CONCLUSIONS

A series of HMBP methylene and difluoromethylene mono-phosphonate ProPAGens were synthesized using the Grubbs olefin metathesis, the first report of this approach in synthesizing the HMBP phosphonate core. These ProPAGens exhibited superior serum stability compared to their phosphate ProPAGEN derivatives, and which we have previously reported.²⁰ Critically, these prodrugs were specific and potent activators of V γ 9/V δ 2 T-cells (femtomolar EC₅₀) in PBMC assays and this translated into potent sensitization of the urinary bladder carcinoma cell line T24 to V γ 9/V δ 2 T-cell-mediated lysis. In PBMC assays, although it is unclear which cells take up the ProPAGens, it has previously been reported that aminobisphosphonates such as zoledronate, as well as the PAG HMBPP, are taken up and “presented” to V γ 9/V δ 2 T-cells by monocytes and dendritic cells (DCs).^{48,49} While this may also be the case for ProPAGens, it is likely they are taken up and processed by a wider range of cells, as they are more lipophilic than zoledronate and HMBPP, allowing intracellular access through diverse cell membranes likely *via* passive diffusion. Enhanced and potentially broadened uptake in PBMC could be responsible for their higher potency compared to HMBPP and zoledronate. Regarding their ability to directly sensitize cancer cells for V γ 9/V δ 2 T-cell-mediated lysis, in the future, it will be beneficial to explore the potency of these ProPAGens against a wider range of cancer targets, as well as assessing the tumor selectivity in comparison to healthy cells. Of relevance to future efforts, substantial levels of V γ 9/V δ 2 T-

cell-mediated killing were observed in T24 killing assays in the absence of ProPAGEN sensitization. This is likely to be affected by several factors, including the activation state of the $\gamma\delta$ T-cells, the levels of endogenous PAG in target cells (e.g., isopentenyl pyrophosphate⁵⁰), and the presence on target cells of ligands for natural killer cell receptors expressed on V γ 9/V δ 2 T-cells such as the Natural Killer Group 2D (NKG2D) and DNAX Accessory Molecule-1 (DNAM1).⁵¹ These factors in combination will likely exert an important influence on V γ 9/V δ 2 T-cell effector responses, but have substantial potential to synergize with ProPAGEN-mediated sensitization.

Collectively, the stability and potency profiles of the new HMBP phosphonate ProPAGens presented in this work make them highly promising candidates for *in vivo* safety and efficacy studies, and future development as new immunotherapeutics for treating challenging cancers and infections that can be targeted by V γ 9/V δ 2 T-cell responses. Regarding their clinical application, these ProPAGens could conceivably either be employed as part or subsequent to a clinical regimen to expand $\gamma\delta$ T-cells *in vivo* or, alternatively, they could be administered to patients receiving adoptive cell therapy with *ex vivo*-expanded $\gamma\delta$ T-cells, to directly augment V γ 9/V δ 2 T-cell-mediated antitumor activity.

EXPERIMENTAL SECTION

General Information. All reagents and solvents were of general purpose or analytical grade and were purchased from Sigma-Aldrich Ltd., Fisher Scientific, Fluorochem, or Acros. ³¹P, ¹H, and ¹³C NMR data were recorded on a Bruker AVANCE DPX500 spectrometer operating at 202, 500, and 125 MHz, respectively. Chemical shifts (δ) are quoted in ppm, and *J* values are quoted in Hz. In reporting spectral data, the following abbreviations were used: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), td (triplet of doublets), and m (multiplet). All of the reactions were carried out under a nitrogen atmosphere and were monitored using analytical thin layer chromatography on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were visualized by illumination under UV light (254 nm) or by the use of KMnO₄ stain followed by heating. Flash column chromatography was performed with silica gel 60 (230–400 mesh) (Merck). HPLC was carried out on a SHIMADZU Prominence-i quaternary low-pressure gradient pump with a Prominence-i UV detector (190 to 700 nm). All solvents for HPLC were HPLC grade purchased from Fisher Scientific. HPLC data analysis was performed using the SHIMADZU Lab solutions software package. The purity of the tested ProPAGens was determined by HPLC, and they were all of \geq 95% purity.

But-3-en-1-ylphosphonic Dichloride (2). Trimethylsilylbromide (13.72 mL, 104.06 mmol, 10 equiv) was slowly added over 30 min to diethylbut-3-en-1-yl phosphonate **1** (2 g, 10.40 mmol, 1 equiv) in DCM (50 mL) under nitrogen at room temperature. The mixture was stirred for 2 h followed by the removal of volatiles under reduced pressure to obtain a yellow liquid δ_p NMR (202 MHz, CDCl₃): 24.70. This was then dissolved in 50 mL of DCM, two drops of dry DMF were added, the mixture was cooled to 0 °C. Oxalyl chloride (2.68 mL, 31.20 mmol, 3 equiv) was then added dropwise, and the reaction mixture was allowed to warm to room temperature and stirred for 18 h. The volatiles were evaporated, and additional DCM (10 mL) was evaporated three more times to give the crude product (1.79 g, 100%) as a brown liquid which was used in the next step without further purification. δ_p NMR (202 MHz, CDCl₃): 49.66.

General Procedure 1. Synthesis of Allylphosphonoamides 3a–d. The crude product but-3-en-1-ylphosphonic dichloride (**2**) was dissolved in 5 mL of DCM and added dropwise to a solution of phenol (1 equiv), dry Et₃N (2 equiv), and DCM (10 mL) at –78 °C. After stirring at –78 °C for 30 min, the reaction mixture was allowed to warm to room temperature, and the stirring was continued for another 3 h. Once the reaction is complete as indicated by ³¹P

NMR [δ_p NMR (202 MHz, CDCl_3): ~39.93], the mixture was filtered, and the volatiles were removed under reduced pressure and washed twice with Et_2O , which was subsequently removed under reduced pressure to give a crude oil. This product was then dissolved in DCM (10 mL) and was added dropwise over 15 min to a stirring mixture of L-alanine ester hydrogen chloride (1 equiv) and dry Et_3N (2 equiv) in dry DCM (10 mL) under nitrogen at -78°C . After stirring at -78°C for 30 min, the reaction was allowed to warm to room temperature and was left stirring overnight. The solvents were removed under reduced pressure, and the mixture was filtered and washed with Et_2O , which was then removed under reduced pressure to give a crude oil. The final products were then purified by column chromatography (6:4 Hex/EtOAc) as colorless oils.

Methyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3a). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine methyl ester hydrogen chloride (0.373 g, 2.23 mmol, 1 equiv) to give product 3a (0.248 g, 38%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 30.88, 31.22. δ_H NMR (500 MHz, CDCl_3): 7.30 (m, 2H, Ar), 7.10 (m, 3H, Ar), 5.82 (m, 1H, $\text{CH}_2=\text{CH}$), 5.00 (m, 2H, $\text{CH}_2=\text{CH}$), 4.11–3.86 (m, 1H, $\text{CH}-\text{NH}$), 3.60 (d, $J = 6.6$ Hz, 3H, OCH_3), 3.18 (m, 1H, NH), 2.48–2.27 (m, 2H, $=\text{CH}-\text{CH}_2$), 1.92 (m, 2H, CH_2-P), 1.21 (2 d, $J = 7.1$ Hz, 3H, $\text{CH}-\text{CH}_3$). δ_C NMR (126 MHz, CDCl_3): 174.68 (d, $J = 6.3$ Hz, $\text{C}=\text{O}$), 174.38 (d, $J = 5.1$ Hz, $\text{C}=\text{O}$), 150.72 (d, $J = 9.1$ Hz), 150.51 (d, $J = 9.4$ Hz), 129.78, 124.78 (d, $J = 5.5$ Hz, $\text{CH}=\text{CH}_2$), 120.86 (d, $J = 4.6$ Hz, C-Ar), 120.71 (d, $J = 4.7$ Hz), 115.56, 52.52 (d, $J = 3.1$ Hz, CH_3-O), 49.58 (d, $J = 14.7$ Hz, $\text{CH}-\text{NH}$), 27.88 (d, $J = 130.9$ Hz, CH_2-P), 27.60 (d, $J = 131.6$ Hz, CH_2-P), 26.59 (d, $J = 4.1$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 21.68 (2 d, $J = 4.3$ Hz, CHCH_3).

Isopropyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3b). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine isopropyl ester hydrogen chloride (0.373 g, 2.23 mmol, 1 equiv) to give product 3b (0.348 g, 48%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 30.93, 31.24. δ_H NMR (500 MHz, CDCl_3): 7.30 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.81 (m, 1H, $\text{CH}_2=\text{CH}$), 5.11 (m, 2H, $\text{CH}_2=\text{CH}$), 4.96 (m, 1H, $\text{CH}-i\text{Pr}$), 4.04–3.94 (m, 1H, $\text{CH}-\text{NH}$), 3.21 (m, 1H, NH), 2.45 (m, 2H, $=\text{CH}-\text{CH}_2$), 2.02–1.88 (m, 2H, CH_2-P), 1.29–1.18 (m, 9H, $\text{CH}_3-\text{CH}-\text{NH}$, $\text{CH}-i\text{Pr}$). δ_C NMR (126 MHz, CDCl_3): 173.67 (d, $J = 6.3$ Hz, $\text{C}=\text{O}$), 150.74 (d, $J = 9.1$ Hz), 129.76 (d, $J = 6.7$ Hz), 124.73 (d, $J = 5.0$ Hz), 120.86 (d, $J = 4.6$ Hz), 120.69 (d, $J = 4.6$ Hz), 115.50, 69.23 (d, $J = 5.6$ Hz, $\text{CH}-i\text{Pr}$), 49.75 (d, $J = 9.5$ Hz, $\text{CH}-\text{NH}$), 27.89 (d, $J = 130.9$ Hz, CH_2-P), 27.54 (d, $J = 131.4$ Hz, CH_2-P), 26.74 (d, $J = 4.3$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 26.57 (d, $J = 4.0$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 21.58 (2 d, $J = 4.4$ Hz, CHCH_3).

tert-Butyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3c). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine tert-butyl ester hydrogen chloride (0.405 g, 2.23 mmol, 1 equiv) to give product 3c (0.461 g, 61%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 30.95, 31.21. δ_H NMR (500 MHz, CDCl_3): 7.32 (m, 2H, Ar), 7.20 (m, 3H, Ar), 5.87 (m, 1H, $\text{CH}_2=\text{CH}$), 5.12 (m, 2H, $\text{CH}_2=\text{CH}$), 4.00–3.86 (m, 1H, $\text{CH}-\text{NH}$), 3.26 (m, 1H, NH), 2.45 (m, 2H, $=\text{CH}-\text{CH}_2$), 2.04–1.85 (m, 2H, $\text{P}-\text{CH}_2$), 1.42 (s, 9H, $t\text{Bu}-\text{H}$), 1.22 (2 d, $J = 7.2$ Hz, 3H, $\text{CH}-\text{CH}_3$). δ_C NMR (126 MHz, CDCl_3): 173.13 (d, $J = 5.5$ Hz, $\text{C}=\text{O}$), 150.77 (d, $J = 9.2$ Hz), 137.43 (d, $J = 7.1$ Hz), 137.32 (d, $J = 7.6$ Hz), 129.76 (d, $J = 6.2$ Hz), 124.71 (d, $J = 4.0$ Hz), 120.88 (d, $J = 4.6$ Hz), 120.72 (d, $J = 4.7$ Hz), 115.47, 81.99 (d, $J = 8.2$ Hz), 60.54, 50.18 (d, $J = 4.0$ Hz, $\text{CH}-\text{NH}$), 28.05, 27.91 (d, $J = 131.6$ Hz, CH_2-P), 27.20 (d, $J = 130.2$ Hz, CH_2-P), 21.82 (2 d, $J = 4.2$ Hz, CHCH_3).

Benzyl (but-3-en-1-yl(phenoxy)phosphoryl)-L-alaninate (3d). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine benzyl ester hydrogen chloride (0.405 g, 2.23 mmol, 1 equiv) to give product 3d (0.461 g, 55%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 30.85, 31.21. δ_H NMR (500 MHz, CDCl_3): 7.38–7.27 (m, 7H, Ar), 7.21–7.18 (m, 2H, Ar), 7.16–7.09 (m, 1H, Ar), 5.85 (m, 1H, $\text{CH}_2=\text{CH}$), 5.04 (m, 4H, $\text{CH}_2=\text{CH}$, $-\text{OCH}_2$), 4.28–4.03 (m, 1H, $\text{CH}-\text{NH}$), 3.24 (m, 1H, NH), 2.56–2.34 (m, 2H, $=\text{CH}-\text{CH}_2$), 2.08–1.82 (m, 2H, $\text{P}-\text{CH}_2$), 1.24 (2 d, $J = 7.1$ Hz, 3H, $\text{CH}-\text{CH}_3$). δ_C NMR (126 MHz, CDCl_3):

173.74 (d, $J = 5.2$ Hz, $\text{C}=\text{O}$), 150.70 (d, $J = 9.1$ Hz), 137.35, 135.40 (d, $J = 6.7$ Hz), 129.79 (d, $J = 6.1$ Hz), 128.79 (d, $J = 2.8$ Hz), 128.64 (d, $J = 6.4$ Hz), 128.33, 120.86 (d, $J = 4.6$ Hz), 120.68 (d, $J = 4.7$ Hz), 115.55, 67.31 (d, $J = 3.0$ Hz, CH_2-O), 49.72 (d, $J = 11.1$ Hz, $\text{CH}-\text{NH}$), 27.88 (d, $J = 130.7$ Hz, CH_2-P), 27.57 (d, $J = 131.3$ Hz, CH_2-P), 26.74 (d, $J = 4.3$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 26.57 (d, $J = 4.1$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 21.70 (2 d, $J = 4.4$ Hz, CHCH_3).

General Procedure for the Synthesis of Phosphonoamidates through Hoveyda–Grubbs Cross Metathesis. To a solution of allylphosphonoamidates 3a–d (1 equiv) and 2-methyl-2-propen-1-ol (85 μL , 1 mmol, 2 equiv), 1,4-benzoquinone (5.40 mg, 10 mol %) in dry DCM (10 mL) was added to Hoveyda–Grubbs catalyst 2nd generation (23.5 mg, 0.038 mmol, 7.5 mol %). The catalyst was added in three equal portions of 2.5 mol % (7.8 mg, 0.013 mmol) at $t = 0, 2,$ and 4 h over the course of the reaction. The solution was then heated to reflux at 45°C under a nitrogen atmosphere for 18 h. After cooling to room temperature, a scoop of activated carbon was added, and the mixture stirred for another 2 h and then filtered through a Celite pad. Volatiles were evaporated, and the residue was purified by extensive silica gel column chromatography (hexane/EtOAc, 7:3 to 0:10) to give 4a–d as colorless oils.

Methyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (4a). Synthesized following general procedure 2 using 3a (150 mg, 0.5 mmol, 1 equiv) to give 4a (91 mg, 57%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 30.89, 31.31. δ_H NMR (500 MHz, CDCl_3): 7.31 (m, 2H, Ar), 7.18 (m, 3H, Ar), 5.48 (m, 1H, $=\text{CH}$), 4.24–3.98 (m, 3H, CH_2OH , $\text{CH}-\text{NH}$), 3.68 (d, $J = 7.9$ Hz, 3H, OCH_3), 3.39–3.18 (m, 1H, NH), 2.55–2.41 (m, 2H, $=\text{CH}-\text{CH}_2$), 2.12–1.87 (m, 2H, CH_2-P), 1.71 (d, $J = 6.6$ Hz, 3H, $\text{CH}_3(\text{CH}_2)\text{C}=\text{O}$), 1.27 (2 \times d, $J = 7.1$ Hz, 3H, $\text{CH}-\text{CH}_3$). δ_C NMR (126 MHz, CDCl_3): 176.71 (d, $J = 5.9$ Hz, $\text{C}=\text{O}$), 150.72, 129.81 (d, $J = 6.9$ Hz), 124.81 (d, $J = 8.6$ Hz, $\text{CH}=\text{CH}_2$), 124.17, 124.04, 120.94, 120.69 (d, $J = 4.6$ Hz), 68.56 (d, $J = 9.1$ Hz, CH_2-OH), 52.64 (d, $J = 3.5$ Hz, CH_3-O), 49.51 (d, $J = 4.1$ Hz, $\text{CH}-\text{NH}$), 28.33 (d, $J = 129.6$ Hz, CH_2-P), 28.06 (d, $J = 130.2$ Hz, CH_2-P), 21.86 (2 d, $J = 4.9$ Hz, CHCH_3), 21.00 (d, $J = 4.8$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 20.89 (d, $J = 4.4$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 13.87. HRMS (ES+, m/z): calcd for $(\text{M} + \text{Na})^+ \text{C}_{16}\text{H}_{24}\text{NO}_5\text{NaP}$, 364.1290; found, 364.1293. HPLC (reverse-phase) 0.5 mL/min MeOH/ H_2O 70:30 in 12 min, $\lambda = 254$ nm, $t_{\text{Rt}} = 5.36$ min (96.5%).

Isopropyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (4b). Synthesized following general procedure 2 using 3b (0.150 g, 0.46 mmol, 1 equiv) to give product 4b (97 mg, 59%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 31.11, 31.49. δ_H NMR (500 MHz, CDCl_3): 7.28 (m, 2H, Ar), 7.20 (m, 3H, Ar), 5.46 (m, 1H, $=\text{CH}$), 4.95 (m, 1H, $\text{CH}-i\text{Pr}$), 4.08–3.79 (m, 3H, CH_2OH , $\text{CH}-\text{NH}$), 3.47–3.25 (m, 1H, NH), 2.51–2.35 (m, 2H, $=\text{CH}-\text{CH}_2$), 2.02–1.85 (m, 2H, CH_2-P), 1.73–1.56 (d, $J = 6.0$ Hz, 3H, $\text{CH}_3(\text{CH}_2)\text{C}=\text{O}$), 1.35–1.08 (m, 9H, $\text{CH}_3-\text{CH}-\text{NH}$, $\text{CH}-i\text{Pr}$). δ_C NMR (126 MHz, CDCl_3): 173.62 (d, $J = 5.8$ Hz, $\text{C}=\text{O}$), 150.74 (d, $J = 9.0$ Hz), 136.76, 124.75, 123.95 (d, $J = 5.4$ Hz), 123.84 (d, $J = 6.9$ Hz), 120.90 (d, $J = 4.5$ Hz), 120.67 (d, $J = 4.6$ Hz), 119.83, 115.58, 69.41 (d, $J = 4.7$ Hz, $\text{CH}-i\text{Pr}$), 68.39 (d, $J = 7.0$ Hz, CH_2-OH), 49.65, 28.36 (d, $J = 129.7$ Hz, CH_2-P), 27.92 (d, $J = 131.1$ Hz, CH_2-P), 21.83 (2 d, $J = 6.2$ Hz, CHCH_3), 20.90 (d, $J = 4.4$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 20.84 (d, $J = 4.4$ Hz, $\text{CH}_2-\text{CH}_2-\text{P}$), 13.84. HRMS (ES+, m/z): calcd for $(\text{M} + \text{Na})^+ \text{C}_{18}\text{H}_{28}\text{NO}_5\text{NaP}$, 392.1603; found, 392.1613. HPLC (reverse-phase) 0.5 mL/min MeOH/ H_2O 70:30 in 12 min, $\lambda = 254$ nm, $t_{\text{Rt}} = 5.23$ min (98%).

tert-Butyl (((E)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (4c). Synthesized following general procedure 2 using 3c (0.150 g, 0.44 mmol, 1 equiv) to give product 4c (108 mg, 64%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 31.05, 31.42. δ_H NMR (500 MHz, CDCl_3): 7.30 (m, 2H, Ar), 7.17 (m, 3H, Ar), 5.46 (m, 1H, $=\text{CH}$), 4.17–3.78 (m, 3H, CH_2OH , $\text{CH}-\text{NH}$), 3.41–3.18 (m, 1H, NH), 2.60–2.30 (m, 2H, $=\text{CH}-\text{CH}_2$), 2.01–1.87 (m, 2H, CH_2-P), 1.69 (d, $J = 6.8$ Hz, 3H, $\text{CH}_3(\text{CH}_2)\text{C}=\text{O}$), 1.42 (s, 9H, $t\text{Bu}$), 1.27 (2 d, $J = 7.9$ Hz, 3H, $\text{CH}-\text{CH}_3$). δ_C NMR (126 MHz, CDCl_3): 173.34 (d, $J = 6.0$ Hz, $\text{C}=\text{O}$), 150.79 (d, $J = 9.0$ Hz), 136.81 (d, $J = 9.6$ Hz), 115.59, 82.22 (d, $J = 5.6$ Hz), 68.45

(d, $J = 10.4$ Hz, $\text{CH}_2\text{-OH}$), 50.07 (d, $J = 4.5$ Hz, CH-NH), 28.01 (d, $J = 129.7$ Hz, $\text{CH}_2\text{-P}$), 27.26 (d, $J = 130.4$ Hz, $\text{CH}_2\text{-P}$), 21.98 (d, $J = 3.8$ Hz, CHCH_3), 20.97 (d, $J = 4.7$ Hz, $\text{CH}_2\text{-CH}_2\text{-P}$), 20.88 (d, $J = 4.4$ Hz, $\text{CH}_2\text{-CH}_2\text{-P}$), 13.86 (CH_3). HRMS (ES^+ , m/z): calcd for $(\text{M} + \text{Na})^+$ $\text{C}_{19}\text{H}_{30}\text{NO}_5\text{NaP}$, 406.1759; found, 406.1762. HPLC (reverse-phase) 0.5 mL/min MeOH/ H_2O 70:30 in 12 min, $\lambda = 254$ nm, $\text{Rt} = 5.41$ min (97%).

Benzyl ((*E*)-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)phosphoryl-L-alaninate (4d). Synthesized following general procedure 2 using **3d** (0.150 g, 0.4 mmol, 1 equiv) to give product **4d** (100 mg, 59%) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3): 30.90, 31.32, δ_{H} NMR (500 MHz, CDCl_3): 7.39–7.28 (m, 7H, Ar), 7.22–7.17 (m, 2H, Ar), 7.12 (m, 1H, Ar), 5.44 (m, 1H, =CH), 5.09 (m, 2H, OCH_2), 4.22–3.86 (m, 3H, m, 3H, CH_2OH , CH-NH), 3.49–3.17 (m, 1H, NH), 2.64–2.36 (m, 2H, =CH- CH_2), 2.04–1.80 (m, 2H, $\text{CH}_2\text{-P}$), 1.69 (d, $J = 6.8$ Hz, 3H, $\text{CH}_3(\text{CH}_2)\text{C}=\text{C}$), 1.33 (2 d, $J = 7.0$ Hz, 3H, CH-CH_3). δ_{C} NMR (126 MHz, CDCl_3): 176.76, 129.81 (d, $J = 7.4$ Hz), 128.75 (d, $J = 14.9$ Hz), 128.39, 124.77, 124.15 (d, $J = 15.0$ Hz), 120.93–120.84, 120.67 (d, $J = 4.7$ Hz), 68.57 (d, $J = 9.6$ Hz), 67.42 (d, $J = 2.9$ Hz), 49.65, 28.05 (d, $J = 129.9$ Hz), 21.77 (d, $J = 4.1$ Hz), 20.87 (d, $J = 4.4$ Hz), 13.87. HRMS (ES^+ , m/z): calcd for $(\text{M} + \text{Na})^+$ $\text{C}_{22}\text{H}_{28}\text{NO}_5\text{NaP}$, 440.1603; found, 440.1609. HPLC (reverse-phase) 0.5 mL/min MeOH/ H_2O 70:30 in 12 min, $\lambda = 254$ nm, $\text{Rt} = 5.18$ min (95%).

Diethyl (1,1-difluorobut-3-en-1-yl)phosphonate (6).³⁷ Anhydrous DMF (20 mL) was added to a 250 mL round bottom flask containing activated zinc powder (2.50 g, 38.23 mmol, 1 equiv) under nitrogen. This was followed by slow dropwise addition of diethyl (bromodifluoromethyl)phosphonate (6.80 mL, 38.23 mmol, 1 equiv), and the mixture was stirred for 3 h at room temperature. CuBr (5.48 g, 38.23 mmol, 1 equiv) was added followed by slow dropwise addition of allyl bromide (3.96 mL, 45.87 mmol, 1.2 equiv) to prevent exothermic reaction. After stirring for 40 h, the mixture was filtered and then partitioned between DCM and 10% aqueous NH_4Cl . The aqueous phase was extracted three times with DCM. The combined organic phases were dried over anhydrous MgSO_4 and concentrated under reduced pressure, and the residue obtained was purified by column chromatography using 20% EtOAc in hexane to give **6** (5.41 g, 62%) as a pale-yellow oil. δ_{p} NMR (202 MHz, CDCl_3): 6.93 (t, $J = 107.4$ Hz). δ_{H} NMR (500 MHz, CDCl_3): 5.84 (m, 1H, =CH), 5.26 (m, 2H, $\text{CH}_2=\text{CH}$), 4.32–4.21 (m, 4H, 2 \times OCH_2CH_3), 2.82 (m, 2H, =CH- CH_2), 1.37 (t, $J = 7.1$ Hz, 6H, 2 \times OCH_2CH_3).

(1,1-Difluorobut-3-en-1-yl)phosphonic Dichloride (7). Synthesized as described for **2** using **6** (2.5 g, 10.95 mmol, 1 equiv) to give the crude product **7** (2.28 g, 100%) as a brown liquid, which was used in the next step without further purification. δ_{p} NMR (202 MHz, CDCl_3): 31.56 (t, $J = 138.8$ Hz).

Methyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (8a). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine methyl ester hydrogen chloride (0.261 g, 1.87 mmol, 1 equiv) to give product **8a** (0.150 g, 24%) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3): 9.05 (dd, $J = 101.1$, 49.9), 8.41 (dd, $J = 100.0$, 51.1 Hz). δ_{H} NMR (500 MHz, CDCl_3): 7.35 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.89 (m, 1H, $\text{CH}_2=\text{CH}$), 5.29 (m, $\text{CH}_2=\text{CH}$), 4.14 (m, 1H, CH-NH), 3.69 (d, $J = 6.6$ Hz, 3H, OCH_3), 3.64 (m, 1H, NH), 3.13–2.84 (m, 2H, =CH- CH_2), 1.38 (2 \times d, 7.1 Hz, 3H, CH-CH_3). δ_{C} NMR (126 MHz, CDCl_3): 173.76 (d, $J = 4.1$ Hz, $\text{C}=\text{O}$), 130.02 (d, $J = 4.1$ Hz), 127.40–127.07 (m), 125.64, 121.54 (d, $J = 9.3$ Hz), 120.54 (t, $J = 4.8$ Hz), 52.69, 50.09 (d, $J = 6.6$ Hz), 39.39–37.22 (m), 21.74 (2d, $J = 3.5$ Hz, CH_3).

Isopropyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (8b). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine isopropyl ester hydrogen chloride (0.314 g, 1.87 mmol, 1 equiv) to give product **8b** (0.165 g, 25%) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3): 9.17 (dd, $J = 101.1$, 30.3 Hz), 8.46 (dd, $J = 99.9$, 38.0 Hz). δ_{H} NMR (500 MHz, CDCl_3): 7.34 (m, 2H, Ar), 7.20 (m, 3H, Ar), 5.89 (m, 1H, $\text{CH}_2=\text{CH}$), 5.29 (m, 2H, $\text{CH}_2=\text{CH}$), 4.99 (m, 1H, CH-iPr), 4.14–

3.99 (m, 1H, CH-NH), 3.68 (m, 1H, NH), 3.00–2.89 (m, 2H, =CH- CH_2), 1.35–1.17 (m, 9H, $\text{CH}_3\text{-CH-NH}$, CH-iPr). δ_{C} NMR (126 MHz, CDCl_3): 172.68 (d, $J = 5.9$ Hz, $\text{C}=\text{O}$), 149.46, 129.88 (d, $J = 4.2$ Hz), 127.11 (d, $J = 5.4$ Hz), 125.46, 121.36 (d, $J = 8.9$ Hz), 120.40 (t, $J = 4.9$ Hz), 69.39 (d, $J = 2.8$ Hz, CH-iPr), 50.15, 38.63–37.99 (m), 21.58 (d, $J = 1.6$ Hz), 21.44 (2 d, $J = 3.2$ Hz, CHCH_3).

tert-Butyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (8c). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine tert-butyl ester hydrogen chloride (0.340 g, 1.87 mmol, 1 equiv) to give product **8c** (0.320 g, 46%) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3): 9.23 (dd, $J = 101.0$, 34.4 Hz), 8.52 (dd, $J = 99.6$, 36.0 Hz). δ_{H} NMR (500 MHz, CDCl_3): 7.34 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.89 (m, 1H, $\text{CH}_2=\text{CH}$), 5.28 (m, 2H, $\text{CH}_2=\text{CH}$), 4.08–3.98 (m, 1H, CH-NH), 3.67 (m, 1H, NH), 3.01–2.84 (m, 2H, =CH- CH_2), 1.42 (d, $J = 5.2$ Hz, 9H, tBu), 1.30 (d, $J = 7.2$ Hz, 3H, CH-CH_3). δ_{C} NMR (126 MHz, CDCl_3): 172.48 (d, $J = 4.5$ Hz, $\text{C}=\text{O}$), 149.72, 129.99 (d, $J = 2.1$ Hz), 128.59–126.95 (m), 125.54, 121.46 (d, $J = 9.2$ Hz), 120.54 (t, $J = 4.8$ Hz), 82.32 (d, $J = 5.8$ Hz), 50.69 (d, $J = 2.8$ Hz, CH-NH), 38.80–38.12 (m), 27.99, 21.85 (2d, $J = 3.1$ Hz, CHCH_3).

Benzyl ((1,1-difluorobut-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (8d). Synthesized following general procedure 1 using phenol (0.210 g, 2.23 mmol, 1 equiv) and L-alanine benzyl ester hydrogen chloride (0.403 g, 1.87 mmol, 1 equiv) to give product **8d** (0.350 g, 45% yield) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3): 9.08 (dd, $J = 101.2$, 45.4 Hz), 8.39 (dd, $J = 100.1$, 46.5 Hz). δ_{H} NMR (500 MHz, CDCl_3): 7.41–7.29 (m, 7H, Ar), 7.25–7.17 (m, 3H, Ar), 5.87 (m, 1H, $\text{CH}_2=\text{CH}$), 5.27 (m, 2H, $\text{CH}_2=\text{CH}$), 5.11 (m, 2H, $-\text{OCH}_2$), 4.33–4.09 (m, 1H, CH-NH), 3.68 (m, 1H, NH), 2.93 (m, 2H, P-CH_2), 1.36 (d, $J = 7.2$ Hz, 3H, CH-CH_3). δ_{C} NMR (126 MHz, CDCl_3): 173.15 (d, $J = 3.2$ Hz, $\text{C}=\text{O}$), 149.68, 135.26 (d, $J = 6.4$ Hz), 130.01 (d, $J = 4.1$ Hz), 128.87–128.52 (m), 128.35 (d, $J = 1.1$ Hz), 127.38–127.03 (m), 125.62, 122.24–120.38 (m), 120.51, 67.49, 50.20, 38.74–38.07 (m), 21.96 (2 d, $J = 3.5$ Hz, CHCH_3).

Methyl (((*E*)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (9a). Synthesized following general procedure 2 using **8a** (0.150 g, 0.45 mmol, 1 equiv) to give product **9a** (97 mg, 58%) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3) δ 9.27 (dd, $J = 112.1$, 18.4 Hz), 8.44 (dd, $J = 126.4$, 20.2 Hz). δ_{H} NMR (500 MHz, CDCl_3): 7.35 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.56 (m, 1H, =CH), 4.18 (m, 1H, CH-NH), 4.07 (m, 2H, =CH- CH_2), 3.75–3.46 (m, 4H, NH, OCH_3), 3.10–2.79 (m, 2H, =CH- CH_2), 1.83 (m, 1H, OH), 1.76 (s, 3H, $\text{CH}_3(\text{CH}_2)\text{C}=\text{CH}$), 1.37 (2 \times d, $J = 7.1$ Hz, 3H, CH-CH_3). δ_{C} NMR (126 MHz, CDCl_3): 176.76, 141.38 (d, $J = 7.6$ Hz), 130.04 (d, $J = 3.2$ Hz), 125.65 (d, $J = 4.0$ Hz), 120.56 (d, $J = 4.6$ Hz), 120.47 (d, $J = 4.7$ Hz), 68.25 (d, $J = 1.9$ Hz), 52.80 ($\text{CH}_3\text{-O}$), 50.09 (d, $J = 4.1$ Hz, CH-NH), 32.82, 21.82 (2 d, $J = 2.6$ Hz, CHCH_3), 14.15 (CH_3). HRMS (ES^+ , m/z): calcd for $(\text{M} + \text{Na})^+$ $\text{C}_{16}\text{H}_{22}\text{F}_2\text{NO}_5\text{NaP}$, 400.1101; found, 400.1109. HPLC (reverse-phase) 0.5 mL/min MeOH/ H_2O 70:30 in 12 min, $\lambda = 254$ nm, $\text{Rt} = 5.45$ min (99%).

Isopropyl (((*E*)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)(phenoxy)phosphoryl)-L-alaninate (9b). Synthesized following general procedure 2 using **8b** (0.150 g, 0.41 mmol, 1 equiv) to give product **9b** (117 mg, 69%) as a colorless oil. δ_{p} NMR (202 MHz, CDCl_3): 9.30 (dd, $J = 109.1$, 34.4 Hz), 8.42 (dd, $J = 111.1$, 38.4 Hz). δ_{H} NMR (500 MHz, CDCl_3): 7.35 (m, 2H, Ar), 7.21 (m, 3H, Ar), 5.56 (m, 1H, =CH), 5.00 (m, 1H, CH-iPr), 4.17–3.91 (m, 3H, CH-NH , =CH- CH_2), 3.67 (m, 1H, NH), 3.08–2.75 (m, 2H, =CH- CH_2), 1.86 (m, 1H, OH), 1.70 (s, 3H, $\text{CH}_3(\text{CH}_2)\text{C}=\text{CH}$), 1.34–1.19 (m, 9H, $\text{CH}_3\text{-CH-NH}$, CH-iPr). δ_{C} NMR (126 MHz, CDCl_3): 173.09 (d, $J = 6.8$ Hz, $\text{C}=\text{O}$), 141.37 (d, $J = 7.9$ Hz), 130.03 (d, $J = 2.6$ Hz), 125.60 (d, $J = 4.4$ Hz), 120.50 (dd, $J = 10.6$, 4.7 Hz), 113.79–113.43 (m), 69.71 (d, $J = 4.5$ Hz), 68.25, 50.29 (d, $J = 9.6$ Hz), 30.88–28.72 (m), 21.73 (d, $J = 8.2$ Hz), 21.84 (2d, $J = 4.1$ Hz, CHCH_3), 14.18 (CH_3). HRMS (ES^+ , m/z): calcd for $(\text{M} + \text{Na})^+$ $\text{C}_{18}\text{H}_{26}\text{F}_2\text{NO}_5\text{NaP}$, 428.1414; found, 428.1414. HPLC (reverse-phase) 0.5 mL/min MeOH/ H_2O 70:30 in 12 min, $\lambda = 254$ nm, $\text{Rt} = 5.46$ min (97.5%).

tert-Butyl (((*E*)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)-(phenoxy)phosphoryl)-L-alaninate (**9c**). Synthesized following general procedure 2 using **8c** (0.150 g, 0.39 mmol, 1 equiv) to give product **9c** (105 mg, 63%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 9.36 (dd, $J = 109.1, 34.4$ Hz), 8.48 (dd, $J = 111.1, 36.4$ Hz). δ_H NMR (500 MHz, CDCl_3): 7.36 (m, 2H, Ar), 7.22 (m, 3H, Ar), 5.56 (m, 1H, =CH), 4.16–3.93 (m, 3H, CH–NH, =CH–CH₂), 3.63 (m, 1H, NH), 3.08–2.77 (m, 2H, =CH–CH₂), 1.90 (m, 1H, OH), 1.71 (s, 3H, CH₃(CH₂)C=CH), 1.43 (d, $J = 5.2$ Hz, 9H, *t*Bu), 1.30 (2 × d, $J = 7.1$ Hz, 3H, CH–CH₃). δ_C NMR (126 MHz, CDCl_3): 172.79 (d, $J = 6.8$ Hz, C=O), 130.02, 125.56 (d, $J = 5.8$ Hz), 120.55 (d, $J = 4.6$ Hz), 120.47 (d, $J = 4.4$ Hz), 82.59, 68.26, 50.72 (d, $J = 7.4$ Hz, CH–NH), 32.97–32.80 (m), 28.02 (d, $J = 1.1$ Hz, 3 × CH₃), 21.98 (2 d, $J = 3.8$ Hz, CHCH₃), 14.16. HRMS (ES+, m/z) calcd. for (M + Na)⁺ C₁₉H₂₈F₂NO₃NaP: 442.1571; found: 442.1578. HPLC (reverse-phase) 0.5 mL/min MeOH/H₂O 80:20 in 12 min, $\lambda = 254$ nm, Rt = 4.87 min (96%).

Benzyl (((*E*)-1,1-difluoro-5-hydroxy-4-methylpent-3-en-1-yl)-(phenoxy)phosphoryl)-L-alaninate (**9d**). Synthesized following general procedure 2 using **8d** (0.150 g, 0.36 mmol, 1 equiv) to give product **9d** (101 mg, 61%) as a colorless oil. δ_p NMR (202 MHz, CDCl_3): 9.21 (dd, $J = 113.2, 22.3$ Hz), 8.37 (dd, $J = 111.1, 24.3$ Hz). δ_H NMR (500 MHz, CDCl_3): 7.39–7.28 (m, 7H, Ar), 7.24–7.16 (m, 3H, Ar), 5.55 (m, 1H, =CH), 5.13 (m, 2H, OCH₂), 4.27–4.14 (m, 1H, CH–NH), 4.06 (m, 2H, =CH–CH₂), 3.68 (m, 1H, NH), 3.05–2.73 (m, 2H, =CH–CH₂), 1.80 (m, 1H, OH), 1.69 (s, 3H, CH₃(CH₂)C=CH), 1.35 (2 × d, $J = 7.1$ Hz, 3H, CH–CH₃). δ_C (126 MHz, CDCl_3): 173.38 (d, $J = 7.9$ Hz, C=O), 149.71, 141.37 (d, $J = 8.3$ Hz), 130.04 (d, $J = 3.1$ Hz), 128.76 (d, $J = 12.8$ Hz), 128.35 (s), 125.63 (d, $J = 5.5$ Hz), 120.49 (dd, $J = 13.7, 4.6$ Hz), 113.75–113.34 (m), 68.25 (d, $J = 2.4$ Hz), 67.61, 50.22 (d, $J = 8.0$ Hz), 34.32–31.18 (m), 21.84 (d, $J = 3.8$ Hz, CHCH₃), 14.15 (CH₃). HRMS (ES+, m/z): calcd for (M + Na)⁺ C₂₂H₂₆F₂NO₃NaP, 476.1414; found, 476.1421. HPLC (reverse-phase) 0.5 mL/min MeOH/H₂O 70:30 in 12 min, $\lambda = 254$ nm, Rt = 6.58 min (96%).

In Silico Docking. Computational studies were performed using the OpenEye molecular modelling software suite provided by the OpenEye Scientific Software (<http://www.eyesopen.com>). An iMac with Intel Core i5/2.9 GHz microprocessor, 8 GB RAM, and running macOS operating system 10.14.1 was used to execute the docking studies. The three-dimensional cocrystal structure of AMP with the human Hint-1 was retrieved from the Protein Data Bank (PDB code 1KPF), and the site of AMP binding was identified as the docking site.⁵² Omega2 was used to generate multiple conformers for metabolite **C** using the default settings.⁵³ FRED (fast rigid exhaustive docking) implements a rigid docking approach to fit these conformers into the predefined binding site and rank the poses by scoring functions.^{54,55} The VIDA module was then used to visualize and inspect the docked poses and identify key interactions between metabolite **C** and Hint-1.

Serum Stability. The experiment was carried out according to a published procedure,⁴³ ProPAGens **4d** or **9d** (5.0 mg) in DMSO (0.050 mL) and D₂O (0.15 mL). After recording the control ³¹P NMR at 37 °C, 0.30 mL of a freshly defrosted human serum aliquot (code: H4522, Sigma, U.K.) was added to the sample, which was next submitted to the ³¹P NMR experiments at 37 °C. The spectra were recorded every 30 min over 12 h. ³¹P NMR recorded data were processed and analyzed using the Bruker TopSpin 2.1 program.

In Vitro Carboxypeptidase Y Assay. The experiment was carried out according to the published protocol.⁴³ This involved dissolving ProPAGens **94** (3.0 mg) in acetone-*d*₆ (0.15 mL), followed by addition of 0.30 mL of T TRIZMA buffer (pH 7.6). After recording the control ³¹P NMR at 25 °C, a previously defrosted carboxypeptidase Y aliquot (0.1 mg dissolved in 0.15 mL of TRIZMA) was added to the sample, which was then immediately submitted to the ³¹P NMR experiments (at 25 °C). The spectra were recorded after 10 min, and every 1 h for 12 h.

Isolation of PBMCs from Healthy Donors. All healthy donors participating in this study were aged over 21 and were recruited from the Institute of Immunology and Immunotherapy, University of

Birmingham. Written informed consent was obtained from all donors prior to any blood withdrawal, and ethical approval was obtained from the NRES Committee West Midlands ethical board (REC reference 14/WM/1254). Approximately 50 mL of peripheral blood (PB) was collected, and PB mononuclear cells (PBMCs) were extracted *via* a ficoll gradient method using Lymphoprep reagent. A volume of 30–35 mL of undiluted whole blood was carefully layered over 15 mL of Lymphoprep, and the cells were then centrifuged at 1200g for 20 min without brake. PBMCs were harvested, washed twice in PBS at 1900 rpm for 5 min, and counted manually using a hemocytometer. The required number of cells was taken for experiments, and any excess was frozen down with freezing media consisting of FCS +10% v/v DMSO. The V γ 9V δ 2 T-cells were identified in all assays by flow cytometric staining as V γ 9+ V δ 2+ population within the live (Zombie Aqua viability dye) CD3+ gate.

In Vitro V γ 9V δ 2 T-Cell Activation Assays. PBMCs were seeded out into round-bottom 96-well plates at 5×10^5 cells in a total volume of 200 μ L per well, and stimulated with zoledronate and HMBPP (concentrations range 1 pM to 100 μ M) and HMBPP ProPAGens, initially at a concentration range of 100 μ M to 10 pM, and then, compounds **4d** and **9d** were selected and tested at 1 aM to 100 μ M in a separate experiment. The cells were incubated at 37 °C/5% CO₂ overnight and were stained by flow cytometry to assess V γ 9V δ 2 T-cell activation on the following day. The staining panel included viability dye (Zombie Aqua; 1:400), CD3 (BV421; 1:100), V γ 9 (PEcy5; 1:400), V δ 2 (APC; 1:400), CD8 (BV650; 1:100), CD69 (PE; 1:25), and CD25 (FITC; 1:100). All samples were acquired using a LSRFortessa X20 (BD Biosciences), and all data were analyzed *via* FlowJo v10 and GraphPad Prism software.

Retroviral Transduction of T24 Cells with GFP. For production of retrovirus encoding green fluorescent protein (GFP), Phoenix cells were transiently transfected with GFP-retroviral vector (kindly provided by Prof. C. Baum, Hannover Medical School, Hannover, Germany) and pCl amphi using Fugene 6 (Promega). The retrovirus particles were collected after 48 h of transfection and were then immobilized to a fibronectin (RetroNectin, Takara)-coated nontissue culture-treated plate (Corning). Subsequently, T24 bladder carcinoma cells (ATCC HTB4) were incubated with the immobilized retrovirus for 72 h at 37 °C. Cells were then acquired on a BD LSRFortessa X20 (BD Biosciences), and GFP expression data were analyzed with FlowJo V10.1.

Cytotoxicity Assay. Prior to carrying out the assay, V γ 9V δ 2 T-cells were expanded *ex vivo* from healthy donor PBMCs with 5 μ M of zoledronate and the addition of 100 U/mL IL2 every 2–3 days over a period of 14 days. On the final day (day 14), GFP + T24 bladder carcinoma cells were cultured for 4 h in the presence of 10 pM ProPAGens or 10 pM HMBPP in round-bottom nontissue culture-treated plates. After washing the plates three times with RPMI medium, expanded V γ 9V δ 2 T-cells were then added, and the cocultures were incubated for 18 h at 37 °C. Cells were then labelled with eFluor 780 fixable viability dye (Invitrogen). Samples were subsequently acquired on a BD LSRFortessa X20 (BD Biosciences), and the data were analyzed with FlowJo V10.1 and Graphpad PRISM 7 (Graphpad Software Inc). The percentage of killing was determined by calculating the number of fixable viability dye + GFP + T24 (dead cells) of the total number of GFP + T24 cells. This assay was performed with $n = 3$ donors.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01232>.

Molecular formula strings (CSV)

Serum stability of HMBP ProPAGen **4d**; LCMS of the *in vitro* enzymatic assay products; *In silico* docking of metabolite **C** in Hint-1; V γ 9/V δ 2 T-cells activation by ProPAGens **4a–d** and **9a–d**; and CD8⁺ T-cells activation by ProPAGens **4d** and **9d** (PDF)

Accession Codes

PDB code 1KPF.

AUTHOR INFORMATION

Corresponding Authors

Benjamin E. Willcox – Cancer Immunology and Immunotherapy Centre and Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, U.K.; orcid.org/0000-0002-6113-2109; Phone: +44 (0) 121 424 9533; Email: b.willcox@bham.ac.uk

Youcef Mehellou – School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, U.K.; orcid.org/0000-0001-5720-8513; Phone: +44 (0) 292 087 5821; Email: MehellouY1@cardiff.ac.uk

Authors

Hachemi Kadri – School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, U.K.

Taher E. Taher – Cancer Immunology and Immunotherapy Centre and Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, U.K.

Qin Xu – School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, U.K.

Maria Sharif – Cancer Immunology and Immunotherapy Centre and Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, U.K.

Elizabeth Ashby – Cancer Immunology and Immunotherapy Centre and Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, U.K.

Richard T. Bryan – Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, U.K.

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.0c01232>

Author Contributions

H.K., T.E.T., Q.X., and M.S. contributed equally. H.K. and Q.X. synthesized the compounds reported in this work and carried out the *in vitro* metabolism assays. T.E.T. and M.S. conducted the biological evaluation of the compounds. E.A. contributed to the initial biological assay validation. R.T.B., B.E.W., and Y.M. designed the experiments and supervised the work. The manuscript was written through contributions of all authors, and all of the authors have given approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): Y.M. and B.E.W. are named inventors on a patent application filed by Cardiff University (GB1810965.2), which covers the compounds discussed in this work.

ACKNOWLEDGMENTS

The work was supported by a Wellcome Trust ISSF grant awarded to Y.M. (Grant code: 514079), a Wellcome Trust Investigator award funding to B.E.W. (Grant code: 099266/Z/12/Z), and a Wellcome Trust Pathfinder award funding to B.E.W. (Grant code: 200983/Z/16/Z).

ABBREVIATIONS

Bn, benzyl; DCM, dichloromethane; BTN2A1, butyrophilin 2A1; BTN3A1, butyrophilin 3A1; Et₃N, triethylamine; HMBP, (E)-4-hydroxy-3-methylbut-2-enyl monophosphate; HMBPP, (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate; IP, isopen-

tenyl pyrophosphate; *i*Pr, isopropyl; Me, methyl; PAg, phosphoantigen; ProPagen, prodrug of a phosphoantigen; TCR, T-cell receptor; *t*Bu, *tert*-butyl; TCR, T-cell receptor; TMSBr, trimethylsilyl bromide

REFERENCES

- (1) Morita, C. T.; Jin, C.; Sarikonda, G.; Wang, H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human V γ 2V δ 2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. *Immunol. Rev.* **2007**, *215*, 59–76.
- (2) Shen, Y.; Zhou, D.; Qiu, L.; Lai, X.; Simon, M.; Shen, L.; Kou, Z.; Wang, Q.; Jiang, L.; Estep, J.; Hunt, R.; Clagett, M.; Sehgal, P. K.; Li, Y.; Zeng, X.; Morita, C. T.; Brenner, M. B.; Letvin, N. L.; Chen, Z. W. Adaptive immune response of V γ 2V δ 2⁺ T cells during mycobacterial infections. *Science* **2002**, *295*, 2255–2258.
- (3) Fisher, J. P.; Heuvelink, J.; Yan, M.; Gustafsson, K.; Anderson, J. $\gamma\delta$ T cells for cancer immunotherapy. *Oncoimmunology* **2014**, *3*, No. e27572.
- (4) Maraka, S.; Kennel, K. A. Bisphosphonates for the prevention and treatment of osteoporosis. *Br. Med. J.* **2015**, *351*, h3783.
- (5) Neville-Webbe, H. L.; Holen, I.; Coleman, R. E. The anti-tumour activity of bisphosphonates. *Canc. Treat. Rev.* **2002**, *28*, 305–319.
- (6) Kunzmann, V.; Bauer, E.; Feurle, J.; Tony, F. W. H.-P.; Wilhelm, M.; Wilhelm, M. Stimulation of $\gamma\delta$ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. *Blood* **2000**, *96*, 384–392.
- (7) Gober, H.-J.; Kistowska, M.; Angman, L.; Jenö, P.; Mori, L.; De Libero, G. Human T cell receptor $\gamma\delta$ cells recognize endogenous mevalonate metabolites in tumor cells. *J. Exp. Med.* **2003**, *197*, 163–168.
- (8) Hewitt, R. E.; Lissina, A.; Green, A. E.; Slay, E. S.; Price, D. A.; Sewell, A. K. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood $\gamma\delta$ T cells in response to aminobisphosphonates is inhibited by statins. *Clin. Exp. Immunol.* **2005**, *139*, 101–111.
- (9) Thompson, K.; Rojas-Navea, J.; Rogers, M. J. Alkylamines cause V γ 9V δ 2 T-cell activation and proliferation by inhibiting the mevalonate pathway. *Blood* **2006**, *107*, 651–654.
- (10) Hintz, M.; Reichenberg, A.; Altincicek, B.; Bahr, U.; Gschwind, R. M.; Kollas, A.-K.; Beck, E.; Wiesner, J.; Eberl, M.; Jomaa, H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human $\gamma\delta$ T cells in *Escherichia coli*. *FEBS Lett.* **2001**, *509*, 317–322.
- (11) Tanaka, Y.; Morita, C. T.; Tanaka, Y.; Nieves, E.; Brenner, M. B.; Bloom, B. R. Natural and synthetic non-peptide antigens recognized by human $\gamma\delta$ T cells. *Nature* **1995**, *375*, 155–158.
- (12) Vavassori, S.; Kumar, A.; Wan, G. S.; Ramanjaneyulu, G. S.; Cavallari, M.; El Daker, S.; Beddoe, T.; Theodossis, A.; Williams, N. K.; Gostick, E.; Price, D. A.; Soudamini, D. U.; Voon, K. K.; Olivo, M.; Rossjohn, J.; Mori, L.; De Libero, G. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human $\gamma\delta$ T cells. *Nat. Immunol.* **2013**, *14*, 908–916.
- (13) Rhodes, D. A.; Chen, H.-C.; Price, A. J.; Keeble, A. H.; Davey, M. S.; James, L. C.; Eberl, M.; Trowsdale, J. Activation of human $\gamma\delta$ T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. *J. Immunol.* **2015**, *194*, 2390–2398.
- (14) Sandstrom, A.; Peigné, C.-M.; Léger, A.; Crooks, J. E.; Konczak, F.; Gesnel, M.-C.; Breathnach, R.; Bonneville, M.; Scotet, E.; Adams, E. J. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human V γ 9V δ 2 T cells. *Immunity* **2014**, *40*, 490–500.
- (15) Wang, H.; Morita, C. T. Sensor function for butyrophilin 3A1 in prenyl pyrophosphate stimulation of human V γ 2V δ 2 T cells. *J. Immunol.* **2015**, *195*, 4583–4594.

- (16) Salim, M.; Knowles, T. J.; Baker, A. T.; Davey, M. S.; Jeeves, M.; Sridhar, P.; Wilkie, J.; Willcox, C. R.; Kadri, H.; Taher, T. E.; Vantourout, P.; Hayday, A.; Mehellou, Y.; Mohammed, F.; Willcox, B. E. BTN3A1 discriminates $\gamma\delta$ T cell phosphoantigens from non-antigenic small molecules via a conformational sensor in its B30.2 domain. *ACS Chem. Biol.* **2017**, *12*, 2631–2643.
- (17) Rigau, M.; Ostrouska, S.; Fulford, T. S.; Johnson, D. N.; Woods, K.; Ruan, Z.; McWilliam, H. E. G.; Hudson, C.; Tutuka, C.; Wheatley, A. K.; Kent, S. J.; Villadangos, J. A.; Pal, B.; Kurts, C.; Simmonds, J.; Pelzing, M.; Nash, A. D.; Hammet, A.; Verhagen, A. M.; Vairo, G.; Maraskovsky, E.; Panousis, C.; Gherardin, N. A.; Cebon, J.; Godfrey, D. I.; Behren, A.; Uldrich, A. P. Butyrophilin 2A1 is essential for phosphoantigen reactivity by $\gamma\delta$ T cells. *Science* **2020**, *367*, No. eaay5516.
- (18) Karunakaran, M. M.; Willcox, C. R.; Salim, M.; Paletta, D.; Fichtner, A. S.; Noll, A.; Starick, L.; Nöhren, A.; Begley, C. R.; Berwick, K. A.; Chaleil, R. A. G.; Pitard, V.; Déchanet-Merville, J.; Bates, P. A.; Kimmel, B.; Knowles, T. J.; Kunzmann, V.; Walter, L.; Jeeves, M.; Mohammed, F.; Willcox, B. E.; Herrmann, T. Butyrophilin-2A1 directly binds germline-encoded regions of the V γ 9V δ 2 TCR and is essential for phosphoantigen sensing. *Immunity* **2020**, *52*, 487–498.
- (19) Hsiao, C.-H. C.; Lin, X.; Barney, R. J.; Shippy, R. R.; Li, J.; Vinogradova, O.; Wiemer, D. F.; Wiemer, A. J. Synthesis of a phosphoantigen prodrug that potently activates V γ 9V δ 2 T-lymphocytes. *Chem. Biol.* **2014**, *21*, 945–954.
- (20) Davey, M. S.; Malde, R.; Mykura, R. C.; Baker, A. T.; Taher, T. E.; Le Duff, C. S.; Willcox, B. E.; Mehellou, Y. Synthesis and biological evaluation of (E)-4-hydroxy-3-methylbut-2-enyl phosphate (HMBP) aryloxy triester phosphoramidate prodrugs as activators of V γ 9/V δ 2 T-cell immune responses. *J. Med. Chem.* **2018**, *61*, 2111–2117.
- (21) Eberl, M.; Hintz, M.; Reichenberg, A.; Kollas, A.-K.; Wiesner, J.; Jomaa, H. Microbial isoprenoid biosynthesis and human $\gamma\delta$ T cell activation. *FEBS Lett.* **2003**, *544*, 4–10.
- (22) Reichenberg, A.; Hintz, M.; Kletschek, Y.; Kuhl, T.; Haug, C.; Engel, R.; Moll, J.; Ostrovsky, D. N.; Jomaa, H.; Eberl, M. Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates its potential to activate human $\gamma\delta$ T cells but does not lead to competitive antagonism. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1257–1260.
- (23) Gossman, W.; Oldfield, E. Quantitative structure–activity relations for $\gamma\delta$ T cell activation by phosphoantigens. *J. Med. Chem.* **2002**, *45*, 4868–4874.
- (24) van Beek, E.; Pieterman, E.; Cohen, L.; Löwik, C.; Papapoulos, S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. *Biochem. Biophys. Res. Commun.* **1999**, *255*, 491–494.
- (25) Sanders, J. M.; Song, Y.; Chan, J. M. W.; Zhang, Y.; Jennings, S.; Kosztowski, T.; Odeh, S.; Flessner, R.; Schwerdtfeger, C.; Kotsikou, E.; Meints, G. A.; Gómez, A. O.; González-Pacanowska, D.; Raker, A. M.; Wang, H.; van Beek, E. R.; Papapoulos, S. E.; Morita, C. T.; Oldfield, E. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. *J. Med. Chem.* **2005**, *48*, 2957–2963.
- (26) Osgerby, L.; Lai, Y.-C.; Thornton, P. J.; Amalfitano, J.; Le Duff, C. S.; Jabeen, I.; Kadri, H.; Miccoli, A.; Tucker, J. H. R.; Muqit, M. M. K.; Mehellou, Y. Kinetin riboside and its ProTides activate the Parkinson's disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization. *J. Med. Chem.* **2017**, *60*, 3518–3524.
- (27) Mehellou, Y.; Valente, R.; Mottram, H.; Walsby, E.; Mills, K. I.; Balzarini, J.; McGuigan, C. Phosphoramidates of 2'- β -D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. *Bioorg. Med. Chem.* **2010**, *18*, 2439–2446.
- (28) Mehellou, Y.; Balzarini, J.; McGuigan, C. An investigation into the anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U) and 2',3'-dideoxyuridine (ddU) phosphoramidate “ProTide” derivatives. *Org. Biomol. Chem.* **2009**, *7*, 2548–2553.
- (29) Mehellou, Y.; Rattan, H. S.; Balzarini, J. The ProTide prodrug technology: from the concept to the clinic. *J. Med. Chem.* **2018**, *61*, 2211–2226.
- (30) Mehellou, Y. The ProTides boom. *ChemMedChem* **2016**, *11*, 1114–1116.
- (31) Clercq, E. D.; Holý, A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. *Nat. Rev. Drug Discovery* **2005**, *4*, 928–940.
- (32) Elliott, T. S.; Slowey, A.; Ye, Y.; Conway, S. J. The use of phosphate bioisosteres in medicinal chemistry and chemical biology. *MedChemComm* **2012**, *3*, 735–751.
- (33) Lentini, N. A.; Foust, B. J.; Hsiao, C.-H. C.; Wiemer, A. J.; Wiemer, D. F. Phosphoramidate prodrugs of a butyrophilin ligand display plasma stability and potent V γ 9V δ 2 T cell stimulation. *J. Med. Chem.* **2018**, *61*, 8658–8669.
- (34) Vougioukalakis, G. C.; Grubbs, R. H. Ruthenium-based heterocyclic carbene-coordinated olefin metathesis catalysts. *Chem. Rev.* **2010**, *110*, 1746–1787.
- (35) McKenna, C. E.; Higa, M. T.; Cheung, N. H.; McKenna, M.-C. The facile dealkylation of phosphonic acid dialkyl esters by bromotrimethylsilane. *Tetrahedron Lett.* **1977**, *18*, 155–158.
- (36) Bessières, M.; Sari, O.; Roy, V.; Warszycki, D.; Bojarski, A. J.; Nolan, S. P.; Snoeck, R.; Andrei, G.; Schinazi, R. F.; Agrofoglio, L. A. Sonication-assisted synthesis of (E)-2-methyl-but-2-enyl nucleoside phosphonate prodrugs. *ChemistrySelect* **2016**, *1*, 3108–3113.
- (37) Martin, B. P.; Vasilieva, E.; Dupureur, C. M.; Spilling, C. D. Synthesis and comparison of the biological activity of monocyclic phosphonate, difluorophosphonate and phosphate analogs of the natural AChE inhibitor cyclophostin. *Bioorg. Med. Chem.* **2015**, *23*, 7529–7534.
- (38) Cheng, J.; Zhou, X.; Chou, T.-F.; Ghosh, B.; Liu, B.; Wagner, C. R. Identification of the amino acid-AZT-phosphoramidate by affinity T7 phage display selection. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6379–6381.
- (39) Murakami, E.; Tolstykh, T.; Bao, H.; Niu, C.; Steuer, H. M. M.; Bao, D.; Chang, W.; Espiritu, C.; Bansal, S.; Lam, A. M.; Otto, M. J.; Sofia, M. J.; Furman, P. A. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. *J. Biol. Chem.* **2010**, *285*, 34337–34347.
- (40) Congiatu, C.; Brancale, A.; McGuigan, C. Molecular modelling studies on the binding of some protides to the putative human phosphoramidase Hint1. *Nucleosides, Nucleotides Nucleic Acids* **2007**, *26*, 1121–1124.
- (41) Davey, M. S.; Lin, C.-Y.; Roberts, G. W.; Heuston, S.; Brown, A. C.; Chess, J. A.; Toleman, M. A.; Gahan, C. G. M.; Hill, C.; Parish, T.; Williams, J. D.; Davies, S. J.; Johnson, D. W.; Topley, N.; Moser, B.; Eberl, M. Human neutrophil clearance of bacterial pathogens triggers anti-microbial $\gamma\delta$ T cell responses in early infection. *PLoS Pathog.* **2011**, *7*, No. e1002040.
- (42) Cochran, J. R.; Cameron, T. O.; Stern, L. J. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. *Immunity* **2000**, *12*, 241–250.
- (43) Slusarczyk, M.; Lopez, M. H.; Balzarini, J.; Mason, M.; Jiang, W. G.; Blagden, S.; Thompson, E.; Ghazaly, E.; McGuigan, C. Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. *J. Med. Chem.* **2014**, *57*, 1531–1542.
- (44) Foust, B. J.; Poe, M. M.; Lentini, N. A.; Hsiao, C.-H. C.; Wiemer, A. J.; Wiemer, D. F. Mixed aryl phosphonate prodrugs of a butyrophilin ligand. *ACS Med. Chem. Lett.* **2017**, *8*, 914–918.
- (45) Foust, B. J.; Li, J.; Hsiao, C. H. C.; Wiemer, D. F.; Wiemer, A. J. Stability and efficiency of mixed aryl phosphonate prodrugs. *ChemMedChem* **2019**, *14*, 1597–1603.
- (46) McGuigan, C.; Murziani, P.; Slusarczyk, M.; Gonczy, B.; Vande Voorde, J.; Liekens, S.; Balzarini, J. Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside. *J. Med. Chem.* **2011**, *54*, 7247–7258.

(47) Townsend, A.; Rothbard, J.; Gotch, F. M.; Bahadur, G.; Wraith, D.; McMichael, A. J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. *Cell* **1986**, *44*, 959–968.

(48) Wei, H.; Huang, D.; Lai, X.; Chen, M.; Zhong, W.; Wang, R.; Chen, Z. W. Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to V γ 2V δ 2 TCR. *J. Immunol.* **2008**, *181*, 4798–4806.

(49) Fowler, D. W.; Copier, J.; Dagleish, A. G.; Bodman-Smith, M. D. Zoledronic acid causes $\gamma\delta$ T cells to target monocytes and down-modulate inflammatory homing. *Immunology* **2014**, *143*, 539–549.

(50) Gertner-Dardenne, J.; Castellano, R.; Mamessier, E.; Garbit, S.; Kochbati, E.; Etienne, A.; Charbonnier, A.; Collette, Y.; Vey, N.; Olive, D. Human V γ 9V δ 2 T cells specifically recognize and kill acute myeloid leukemic blasts. *J. Immunol.* **2012**, *188*, 4701–4708.

(51) Rincon-Orozco, B.; Kunzmann, V.; Wrobel, P.; Kabelitz, D.; Steinle, A.; Herrmann, T. Activation of V γ 9V δ 2 T cells by NKG2D. *J. Immunol.* **2005**, *175*, 2144–2151.

(52) Lima, C. D.; Klein, M. G.; Hendrickson, W. A. Structure-based analysis of catalysis and substrate definition in the HIT protein family. *Science* **1997**, *278*, 286–290.

(53) Hawkins, P. C. D.; Nicholls, A. Conformer generation with OMEGA: learning from the data set and the analysis of failures. *J. Chem. Inf. Model.* **2012**, *52*, 2919–2936.

(54) McGann, M. FRED pose prediction and virtual screening accuracy. *J. Chem. Inf. Model.* **2011**, *51*, 578–596.

(55) McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, F. K. Gaussian docking functions. *Biopolymers* **2003**, *68*, 76–90.